Education
About Us
Working with TipRanks
Follow Us
Johanna Friedl-Naderer Insider Profile
4 Followers
Johanna Friedl-Naderer, EVP & COO at Vir Biotechnology, holds 96.20K shares in Dyne Therapeutics (Ticker: DYN), holds 148.52K shares in Vir Biotechnology (Ticker: VIR).
Johanna Friedl-Naderer has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Johanna Friedl-Naderer holds in companies
Most Profitable Insider Trade
The most profitable trade made by Johanna Friedl-Naderer
Johanna Friedl-Naderer's Trading History
Vir Biotechnology
Mar 07, 2023
EVP & COO
Informative Sell
33.82K
$1.18M
Dyne Therapeutics
Dec 06, 2024
CCO
Uninformative Buy
―
$1.19M
List of latest transactions for each holding click on a transaction to see Johanna Friedl-Naderer's performance on stock
You May Also Like
Johanna Friedl-Naderer insider profile FAQ
What is the percentage of profitable transactions made by Johanna Friedl-Naderer?
The percentage of profitable transactions made by Johanna Friedl-Naderer is ―.
What is the average return per transaction made by Johanna Friedl-Naderer?
The average return per transaction made by Johanna Friedl-Naderer is ―.
What stocks does Johanna Friedl-Naderer hold?
Johanna Friedl-Naderer holds: VIR, DYN stocks.
What was Johanna Friedl-Naderer’s latest transaction?
Johanna Friedl-Naderer latest transaction was an Uninformative Buy of ―.
What was Johanna Friedl-Naderer's most profitable transaction?
Johanna Friedl-Naderer’s most profitable transaction was an Informative Sell of VIR stock on March 7, 2023. The return on the trade was 50.50%.
What is Johanna Friedl-Naderer's role in Vir Biotechnology?
Johanna Friedl-Naderer's role in Vir Biotechnology is EVP & COO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.